Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-31 @ 4:51 AM
Study NCT ID:
NCT07316361
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2026-01-07
First Post:
2025-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Sponsor:
Biogenea Pharmaceuticals Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-02-02
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-12-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-12-02
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-08
First Submit QC Date:
None
Study First Post Date:
2026-01-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-01-05
Last Update Post Date:
2026-01-07
Last Update Post Date Type:
ACTUAL